tiprankstipranks
The Fly

Abivax initiated with an Outperform at JMP Securities

Abivax initiated with an Outperform at JMP Securities

JMP Securities initiated coverage of Abivax (ABVX) with an Outperform rating and $33 price target Abivax is focused on the development and commercialization of obefazimod, a novel immune modulator for the treatment of inflammatory bowel diseases, the analyst tells investors in a research note. The firm says the company has demonstrated “robust” Phase 2b results in patients with moderate-to-severe ulcerative colitis and results from two Phase 3 induction trials are anticipated in early Q2 of 2025. It believes the commercial potential for obefazimod is “compelling.”

Published first on TheFly – the ultimate source for real-time, market-moving breaking financial news. Try Now>>